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Abstract
Background: High-risk human papilloma virus (HR-HPV) infection is associated with the development of cervical
cancer. HPV vaccination reduces the risk of developing malignant lesions and is expected to change the dynamics
of HPV transmission. Data from non-vaccinated women may provide an important benchmark to allow the impact
of HPV vaccination programs to be assessed.
This study was designed to prospectively determine the changing dynamics of HR-HPV infection and associated
genital diseases in young women, most of whom were non-vaccinated.
Methods: Data from a population-based cohort study, comprising women of two predefined birth cohorts (women
born in 1983/84 or 1988/89), were analyzed between 19 October 2009 and 31 December 2010 to determine risk
factors for high-risk HPV infection and the association between specific HR-HPV types and atypical Pap smear test
results. HPV status was determined by Hybrid Capture 2 (HC2) assay and genotyping.
Results: The prevalence of HR-HPV was 22.8% in the 1983/84 cohort (150/659) and 23.7% in the 1988/99 cohort
(142/599). Only the number of sexual partners was a significant risk factor for HPV infection (odds ratios 22.687 and
6.124 for more than five versus one partner 84 cohort,/84 and 1988/89 cohorts, respectively) in multivariate analysis.
HPV16 positive-women were significantly more likely to have abnormal Pap smears of any degree than HPV16-
negative women (22.0% versus 3.61%, p < 0.0001 for the 1983/84 cohort and 9.09% versus 2.52%, p = 0.0482 for the
1988/89 cohort). CIN3 was diagnosed in six women 84 cohort,/84 cohort and two in the 1988/89 cohort. All
women with CIN3 tested positive for HC2-HR and all six CIN3 cases 84 cohort,/84 cohort tested positive for HPV16.
In the 1988/89 cohort, the rate of HPV16 infection was significantly lower in vaccinated than non-vaccinated
women (1.59% versus 8.88%; p = 0.003).
Conclusions: HR-HPV infection was highly prevalent in both cohorts and associated with an increased risk of
abnormal Pap smears and biopsy proven CIN2+. HPV16 infection was associated with a high risk of clinically
relevant lesions. HPV vaccination significantly decreased the risk of HPV16 infection.
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Background
Thirteen types of human papilloma virus (HPV) are as-
sociated with the development of cervical cancer and are
designated as high-risk (HR) [1]. Among the HR types,
HPV types 16 and 18 are associated with 70% of all
cervical cancer cases [2]. Prophylactic vaccines directed
against the HR types 16 and 18 prevent infection of the
cervical epithelium and other squamous epithelia, de-
creasing the development of premalignant lesions [3,4].
The best results of prophylactic vaccination are achieved
by vaccinating women before they become sexually ac-
tive and genitally infected [5].
Vaccination programs are expected to change the dy-
namics of HPV transmission [6] and, therefore, it is im-
perative to monitor the burden of HPV infections and
associated diseases in young women who had reached
the age of 18 years or more prior to the implementation
of routine vaccination. German groups have already
published epidemiological data from HPV and cervical
cancer screening trials [7-10], but most of these trials ex-
cluded women younger than 30 years of age. An obser-
vational study reported by Iftner and colleagues included
1692 females aged 10–30 years, but the one-time cross-
sectional analysis provided only limited clinical informa-
tion [10]. In Germany, a national, reimbursed annual
screening program with Pap (Papanicolaou) smear test-
ing starts for women at age 20 years and data show that
atypical screening results are reasonably common in
women aged 20–25 years and even more so in those
aged 25–30 years [11]. In the German screening pro-
gram, women have to attend a gynecologist in private
practice. Since 2006, gynecologists in private practice in
Wolfsburg have formed an experienced screening and
referral network with the Klinikum Wolfsburg to im-
prove cervical cancer prevention. This collaboration has
provided a final opportunity to prospectively study the
dynamics of HPV infection and associated genital dis-
eases in a population comprising mostly non-vaccinated
young women in Wolfsburg, Germany. This paper re-
ports the results on the prevalence of HR-HPV types
and associated diseases. Data for low-risk (LR)-HPV are
published separately [12].
Methods
The Wolfsburg HPV Epidemiological Study (WOLVES)
is a prospective, population-based surveillance study on
the prevalence and incidence of HPV infections and as-
sociated diseases in women of three predefined birth co-
horts. All women born in 1983/84, 1988/89, and 1993/
94 with a first residency in Wolfsburg, Germany (popu-
lation 123,000), will be invited to participate. This ana-
lysis includes baseline data for the 1983/84 and 1988/89
cohorts.
Study population
The residents’ registration office provided a list of women
with a first residency in Wolfsburg born in either 1983/84
or 1988/89 and all 2850 women were invited by letter to
attend cervical cancer screening. The invitation included
information on the study objectives and made it clear that
participation was voluntary. To be recruited, women had
to attend one of 20 gynecologists in private practices in
the city of Wolfsburg for routine Pap smear screening,
according to the standard screening concept in Germany.
All participants gave written consent and the study was
approved by the ethics committee of the physicians’ asso-
ciation of Lower Saxony in Hannover, Germany.
Participants completed a short, standardized question-
naire in the private practice. The questionnaire included
questions on education, birth country, marital status,
pregnancies, parity, contraception, smoking, number of
sexual partners, age at sexual debut, prior screening for
cervical cancer, history of abnormal Pap smears, sexually
transmitted infections and genital warts. Furthermore, the
referring gynecologist collected information on HPV vac-
cination status by checking the certificate of vaccination.
Participants underwent a pelvic examination with vi-
sualization of the uterine cervix. Pap smears were taken
using spatula and endocervical brush. A second sample
was then obtained with a Qiagen Cervical Sampler
(Medscan, Uppsala, Sweden), and suspended in 1 ml of
specimen transport medium (STM/Qiagen Inc., Hilden,
Germany) for HPV DNA testing.
HPV testing
All primary HPV testing was undertaken using the Hy-
brid Capture 2 (HC2) assay (HC2/Qiagen Inc., Hilden
Germany). All samples were analyzed for the presence of
at least 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68) following the manufacturer’s in-
structions. A positive HR-HPV result in this study refers
to a subject positive for the HR-HPV probe mix. In this
analysis, HR HPV subtypes were counted individually. In
patients with multiple infections, HR HPV subtypes were
reported separately. LR-HPV types (6, 11, 42, 43 and 44)
are reported in a separate publication [12].
All samples that tested positive for HR-HPV with HC2
and 10% (every tenth) of all HC2-negative samples
underwent HPV genotyping. HPV genotyping was per-
formed as described previously using SPF-10-PCR,
followed by Reverse Line Probe Assay LiPA Extra (SPF-
10-PCR) [13]. Briefly, total DNA was isolated from the
cervical samples with the use of a MagNAPure device
(Roche, Indianapolis, IN) and analyzed with INNO-LiPA
Extra HPV prototype assay (Innogenetics, Inc, Gent,
Belgium) according to the manufacturer’s instructions.
The INNO-LiPA Extra test identifies established HR-
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
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and 68 [1]) and five known or putative high-risk types
(26, 53, 66, 73 and 82) [14,15]. Polymerase chain reac-
tion (PCR) was performed according to good laboratory
practice in a laboratory separate from other laboratory
rooms. All PCR reactions were performed with 10 μl in-
put DNA in a final volume of 50 μl using reagents pro-
vided by Innogenetics, 10 min 37°C, 9 min 94°C, and
40 cycles of 30 sec of denaturation at 94°C, followed by
45 sec of 52°C annealing temperature and 45 sec of ex-
tension at 72°C run on a MJ Thermocycler PCT 200.
The PCR product was then denatured and a 10 μl ali-
quot hybridized to one strip at 49°C for 60 min, followed
by multiple washing steps. The strips were analyzed on a
flatbed scanner with the use of LiRAS prototype soft-
ware (Innogenetics, Inc), which displays the patterns and
relative intensity of positive bands as arbitrary grey-tone
values between 0.1 and 1.0.
Pap smears and colposcopy
A standardized, risk-adapted follow-up protocol was
used for the management of participants according to
the results of conventional Pap smear testing and HPV
status, as described previously [16].
Patients were transferred for colposcopy if they had
abnormal Pap smears conspicuous of high-grade lesions
or had Pap smears classified as borderline/low-grade and
tested positive for HR-HPV. Colposcopists classified the
type of transformation zones according to the Barcelona
nomenclature of the International Federation for
Cervical Pathology and Colposcopy (IFCPC) [17]. Col-
poscopy findings were classified as minor changes
(physiological changes and HPV infections with or with-
out cervical intraepithelial neoplasia 1 [CIN1]) and
major changes (CIN2+). For both categories separate
measurements were made of the speed and intensity of
acetowhite reactions and the morphology (condyloma
like, flat, punctuation, mosaic). In cases of type 1 or type
2 transformation zone with visible squamous columnar
junction, colposcopy was regarded as satisfactory. Any
visible lesion underwent histological assessments with
punch biopsies. No random punch biopsies were taken if
colposcopy findings were normal. Histological assess-
ment was mandatory for any lesion where there was a
suspicion of high-grade neoplasia.
Statistical analysis
This paper presents a one-time cross-sectional analysis
of data for the 1983/84 cohort and baseline data for the
1988/89 cohort. As this is an observational study, no for-
mal hypothesis was tested and the statistical analysis was
descriptive for all evaluable variables. All statistical ana-
lyses were undertaken by an independent statistician
who did not participate in the collection of data. The as-
sociation between HR-HPV infection and exploratory
variables was analyzed in univariate analysis with a level
of significance defined as p < 0.05 (two-sided testing).
Multivariate analyses include data on exploratory vari-
ables for all HPV subtypes. All statistical analyses were
performed with the validated program Testimate Version
6.5 from IDV Gauting (validation of software, hardware
and user according to FDA 21 CFR Part 11).
Results
Study population
Between 19 October 2009 and 31 December 2010, 659
(43.8%) of 1504 registered women born in 1983/84 and
599 (44.5%) of 1346 women born in 1988/89 were
recruited. The characteristics and risk factors of interest
for the two cohorts are shown in Table 1. In general,
there were no notable differences between the two birth
cohorts. The fact that patients in the 1988/89 cohort
were younger than those 84 cohort,/84 cohort explains
some of the numerical differences, such as in education,
evident in Table 1.
Prevalence of HR-HPV infection
HC2 test results for HC2 HR-positive and LR-/HR-posi-
tive are shown in Figure 1. Overall, HR-HPV infection
was identified by HC2 testing in 292/1258 women
(23.2%; 95% confidence interval [CI] 20.9–25.6%). The
prevalence of HR-HPV was 22.8% (95% CI 19.6–26.2%)
84 cohort,/84 cohort (150/659) and 23.7% (95% CI
20.4%–27.3%) in the 1988/99 cohort (142/599).
The type-specific HR-HPV prevalence is shown in
Figure 2. In the 1983/84 cohort, the most frequent;
HR-HPV types were 16 (7.59%) followed by types 51
(5.31%), 31 and 53 (both 4.1%), 52 (3.79%), 66 (3.49%), 39
(2.88%), and 18 (2.12%). In the 1988/89 cohort the most
frequent HR-HPV types were 51 (9.35%), 16 (7.35%), 52
(4.51%), 31, 53 and 66 (all 4.01%), and 18 (2.84%).
Cofactors associated with HR-HPV infection
Univariate analysis showed that the number of sex part-
ners (strong), early age at first intercourse (strong),
and smoking (weak) were significant risk factors for
HR-HPV infection in the 1983/84 cohort, whereas
there were weaker associations in the 1988/89 cohort
(Figure 3) [18]. Other parameters (contraception, history
of STDs and age at first menstrual period) did not show
any association with HR-HPV infection.
The three cofactors associated with HR-HPV infection
were analyzed by specific HR-HPV type using the Mann
Witney U test, two-sided for HPV-positive (test) versus
HPV-negative (reference). In the 1983/84 cohort, the as-
sociation between HPV16 infection and both the num-
ber of partners (>5 vs 1; p = 0.0000) and early age at first
sex (p = 0.0065) was stronger than for HR-types overall.
No association was evident in the 1988/89 cohort.
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In multivariate analysis, only the number of sexual
partners was a significant risk factor for HPV infection.
The odds ratios (ORs) were 22.687 (95% CI 8.032–
64.086) and 6.124 (95% CI 3.195–11.738) for more than
five partners versus one partner in the 1983/84 and
1988/89 cohorts, respectively.
Genotypes and atypical Pap smear test results
The association between atypical Pap smear test results
and specific HR-HPV types is detailed in Table 2.
HPV16 positive-women were significantly more likely to
have abnormal Pap smears of any degree than were
HPV16-negative women. In the 1983/84 cohort, the risk
of > PapII (ASC-US [Atypical squamous cells of uncertain
significance] or more) was 22.0% (95% CI 11.53–35.96%)
in HPV16-positive women compared with 3.61% (95% CI
2.28–5.42%) in HPV16-negative women (p < 0.0001). In
the 1988/89 cohort, the corresponding risks were 9.09%
(95% CI 2.53 – 21.67%) in HPV16-positive women and
2.52% (95% CI 1.39–4.20%) in HPV16-negative women
(p = 0.0482). Similarly, but in the 1983/84 cohort only,
HPV16-positive women had a significantly increased risk
for atypical Pap smears classified low-grade squamous
intraepithelial lesion (LSIL) or more (p < 0.0001) and for
biopsy proven CIN1+ (p < 0.0001).
In HPV18-positive women in the 1983/84 cohort, the
corresponding risks were significantly increased for atyp-
ical Pap smears classified borderline or more (p < 0.0034),
LSIL or more (p < 0.0088) and CIN1+ (p < 0.04). No sig-
nificant differences were observed in the 1988/89 cohort.
Type-specific univariate analyses of data from the
1983/84 cohort showed significant interactions between
other specific HPV types and atypical Pap smear test re-
sults. There was a weak association between HPV39 and
Table 1 Patient characteristics, including risk factors
Cohort (n, unless stated
otherwise)a
1983/84 1988/89
Number recruited 659 599
Highest graduation
None 21 (3%) 6 (1%)
Secondary school 354 (54%) 372 (62%)
Higher level 283 (43%) 221 (37%)
Country of birth
Germany 474 (72%) 511 (85%)
Other 183 (28%) 88 (15%)
Stable relationship
Yes 529 (80%) 423 (71%)
No 123 (19%) 169 (28%)
Current pregnancy
Yes 27 (4%) 11 (2%)
No 627 (95%) 581 (97%)
Parity (mean ± SD)
Pregnancies 0.7 ± 1.05 0.2 ± 0.56
Born children 0.5 ± 0.74 0.1 ± 0.36
Screening for cervical cancer
Yes 548 (83%) 307 (51%)







Yes 244 (37%) 221 (37%)
No 413 (63%) 377 (63%)
Former
Yes 163 (25%) 74 (12%)
No 345 (52%) 392 (65%)
Number of sexual partners
0 8 (1%) 30 (5%)
1 125 (19%) 126 (21%)
2–5 335 (51%) 336 (56%)
>5 162 (25%) 91 (15%)
Age at sexual debut (mean ± SD) 16.9 ± 2.45 16.1 ± 1.67
Pap smear test
I 2 (<1%) 2 (<1%)
II 624 (95%) 579 (97%)
IIw 11 (2%) 12 (2%)
III 3 (<1%) 1 (<1%)
Table 1 Patient characteristics, including risk factors
(Continued)
IIID 18 (3%) 5 (<1%)
Iva 1 (<1%) –
History of sexually transmitted disease
Yes 11 (2%) 4 (<1%)
No 648 (98%) 594 (99%)
History of genital warts
Yes 26 (4%) 2 (<1%)
No 633 (96%) 163 (27%)
HPV vaccination
No 616 (93%) 463 (77%)
Yes 42 (6%) 136 (23%)
Full 3 courses 40 (6%) 126 (21%)
a Missing data are not included so n does not always add up to
number recruited.
b Multiple methods counted in the same individual.
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Pap LSIL or more (p < 0.0239). HPV51 showed a weak
association with Pap ASC-US or more (p < 0.0318), but
a stronger association with Pap smears LSIL or more
(p < 0.0047) and histology of CIN1+ (p < 0.0066). HPV53
showed a significant association with Pap ASC-US or
more (p < 0.0093) and LSIL or more (p < 0.0107), but
not with CIN1+. HPV66 showed significant associations
with Pap ASC-US + (p < 0.0005), LSIL (p < 0.0005) and
CIN1+ (p < 0.0134). HPV types 31, 33, 35, 45 and 52
showed no associations at all.
For the 1988/89 cohort, type-specific univariate ana-
lysis found no association between HPV types 31, 33, 35,
39, 45, 51, 53 and 66 and atypical smear tests; however,
there was a significant association between HPV52
(n = 27) and Pap smears LSIL or more (p < 0.0284)
CIN2 and CIN3 and associated HPV types
Overall eight women were diagnosed with CIN3, six in the
1983/84 cohort and two in the 1988/89 cohort. All women
with CIN3 tested positive for HC2-HR. Genotyping
showed that all six CIN3 cases in the 1983/84 cohort
tested positive for HPV16 (as single infections in two cases
and as co-infections with HPV51 in two cases, HPV52 in
one case and HPV35 in one case). For HPV16-infected
women in the 1983/84 cohort the corresponding risk for
CIN3 was 6/50 (12%). In the 1988/89 cohort, genotyping
showed one case of co-infection with HPV16 and HPV52,
but failed in the other case.
Overall 11 women were diagnosed with CIN2, six
in the 1983/84 cohort and five in the 1988/89 cohort.
All tested positive for HC2-HR. Genotyping showed
that three cases of CIN2 in the 1983/84 cohort were
associated with HPV16 (one HPV16, 39 and 66, one
HPV16, 52 and 66 and one HPV16 and 66) while the
remaining cases were associated with HPV18 (n = 1),
HPV18 and 31 (n = 1) and HPV53 (n = 1). In the
1988/89 cohort, genotyping showed four cases of
CIN2 were associated with HPV16 (two HPV16 only,
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Figure 2 Type-specific prevalence of HR (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and putative HR (26, 53, 66, 73, and 82)
HPV infection in 1983/84 and 1988/89 cohorts.
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History of cone biopsies/excisional treatment
Five women in the 1983/84 cohort had a history
of conization because of CIN3, whereas there were
no cases with a history of conization in the 1988/89
cohort.
Colposcopy morphology and association with HPV types
In total, 46 women were referred to colposcopy, all of
whom had transformation zones either type 1 (n = 28) or
type 2 (n = 18). Colposcopy was considered to be satis-















83/84 HPV HR positive (test) vs. 83/84 HPV HR negative (reference)
Wilcoxon-Mann-Whitney-U-Test, two-sided, 95.0% CI
0.29/0.71 = large difference; 0.36/0.64 medium-sized difference; 0.44/0.56 small difference; 0.50 equality
Superiority: 83/84 HR positive
A
Superiority: 83/84 HR negative

















































88/89 HPV HR positive (test) vs. 88/89 HPV HR negative (reference)
Wilcoxon-Mann-Whitney-U-Test, two-sided, 95.0% CI
0.29/0.71 = large difference; 0.36/0.64 medium-sized difference; 0.44/0.56 small difference; 0.50 equality
Superiority: 88/89 HR positive
Superiority: 88/89 HR negative




































Figure 3 Univariate analysis of risk factors for HR-HPV infection in (A) in 1983/84 cohort and (B) 1988/89 cohort. In this analysis, the
Mann Witney measure (0.0 to 1.0) reflects the probability that a randomly selected patient from the test group is better off than a randomly
selected patient from the control group. Benchmark values are: 0.36 medium-sized inferiority, 0.44 small inferiority, 0.50 equality, 0.56 small
superiority, 0.64 medium-sized (relevant) superiority, and 0.71 large superiority. For non-inferiority the benchmark is defined as MW-measure = 0.36
(medium-sized inferiority), for superiority the benchmark is defined as MW-measure = 0.50 (equality). The medium-sized superiority (inferiority) is –
per definition – a medically relevant group-difference [18].
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Prevalence of atypical Pap smear test results (%, 95% CIs) according to infection with specific HR-HPV types
1983/84 cohort (n = 659) 1988/89 cohort (n = 599)
HPV status ASC-US or more >LSIL CIN1+ HPV status ASC-US or more >LSIL CIN1+
HPV16 Negative 3.61 2.30 1.31 Negative 2.52 0.90 0.90
(n = 609) (2.28-5.42) (1.26-3.83) (0.57-2.57) (n = 555) (1.39-4.20) (0.29-2.09) (0.29-2.09)
Positive 22.00 16.00 14.00 Positive 9.09 2.27 4.55
(n = 50) (11.53-35.96) (7.17-29.11) (5.82-26.74) (n = 44) (2.53-21.67) (0.06-12.02) (0.56-15.47)
HPV18 Negative 4.50 2.95 2.02 Negative 2.75 1.03 1.03
(n = 645) (3.03-6.39) (1.78-4.56) (1.08-3.42) (n = 582) (1.58-4.43) (0.38-2.23) (0.38-2.23)
Positive 28.57 21.43 14.29 Positive 11.76 0 5.88
(n = 14) (8.39-58.10) (4.66-50.80) (1.78-42.81) (n = 17) (1.46-36.44) (0–19.51) (0.15-28.69)
HPV31 Negative 5.22 3.48 2.37 Negative 2.78 1.04 1.04
(n = 632) (3.62-7.26) (2.19-5.22) (1.33-3.88) (n = 575) (1.60-4.48) (0.38-2.26) (0.38-2.26)
Positive 0 0 0 Positive 8.33 0 4.17
(n = 27) (0–1.28) (0–1.28) (0–12.77) (n = 24) (1.03-27.00) (0–14.25) (0.11-21.12)
HPV33 Negative 5.05 3.36 2.29 Negative 3.03 1.01 1.18
n = 654) (3.50-7.01) (2.11-5.05) (1.29-3.75) (n = 594) (1.81-4.75) (0.37-2.19) (0.48-2.41)
Positive 0 0 0 Positive 0 0 0
(n = 5) (0–52.18) (0–52.18) (0–52.18) (n = 5) (0–52.18) (0–52.18) (0–52.18)
HPV35 Negative 4.88 3.35 2.13 Negative 3.02 1.01 1.17
(n = 656) (3.36-6.82) (2.11-5.03) (1.17-3.55) (n = 597) (1.80-4.72) (0.37-2.17) (0.47-2.40)
Positive 33.33 0 33.33 Positive 0 0 0
(n = 3) (0.84-90.57) (0–70.76) (0.84-90.57) (n = 2) (0–84.19) (0–84.19) (0–84.19)
HPV39 Negative 4.69 2.97 2.19 Negative 3.06 1.02 1.19
(n = 640) (3.18-6.62) (1.80-4.60) (1.20-3.64) (n = 589) (1.82-4.79) (0.37-2.20) (0.48-2.43)
Positive 15.79 15.79 5.26 Positive 0 0 0
(n = 19) (3.38-39.58) (3.38-39.58) (0.13-26.03) (n = 10) (0–30.85) (0–30.85) (0–30.85)
HPV51 Negative 4.49 2.72 1.76 Negative 2.58 0.55 1.10
(n = 624) (3.00-6.42) (1.59-4.33) (0.88-3.13) (n = 543) (1.42-4.29) (0.11-1.61) (0.41-2.39)
Positive 14.29 14.29 11.43 Positive 7.14 5.36 1.79
(n = 35) (4.81-30.26) (4.81-30.26) (3.20-26.74) (n = 56) (1.98-17.29) (1.12-14.87) (0..05-9.55)
HPV52 Negative 4.89 3.15 2.21 Negative 2.80 0.70 1.05
(n = 634) (3.35-6.87) (1.94-4.83) (1.21-3.68) (n = 572) (1.61-4.50) (0.19-1.78) (0.39-2.27)
Positive 8.00 8.00 4.00 Positive 7.41 7.41 3.70
(n = 25) (0.98-26.03) (0.98-26.03) (0.10-20.35) (n = 27) (0.91-24.29) (0.91-24.29) (0.09-18.97)
HPV53 Negative 4.43 2.85 2.06 Negative 2.78 0.87 1.22
(n = 632) (2.96-6.34) (1.70-4.46) (1.10-3.49) (n = 575) (1.60-4.48) (0.28-2.02) (0.49-2.49)
Positive 18.52 14.81 7.41 Positive 8.33 4.17 0
(n = 27) (6.30-38.08) (4.19-33.73) (0.91-24.29) (n = 24) (1.03-27.00) (0.11-21.12) (0–14.25)
HPV66 Negative 4.25 2.67 1.89 Negative 2.78 0.87 1.04
(n = 636) (2.82-6.12) (1.56-4.25) (0.98-3.27) (n = 575) (1.6-4.48) (0.28-2.02) (0.38-2.26)
Positive 26.09 21.74 13.04 Positive 8.33 4.17 4.17
(n = 23) (10.23-48.41) (7.46-43.70) (2.78-33.59) (n = 24) (1.03-27.00) (0.11-21.12) (0.11-21.12)
aHPV subtypes were counted individually. In patients with multiple HR HPV infections, the data are reported for each subtype separately, e.g. a mixed HPV16/52
infection is included in the rows for both HPV16 and for HPV52.
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classified as major changes in 11 cases, minor changes
in 25 cases and as normal in 10 cases.
All eight CIN3 lesions showed major changes with fast
acetic acid reaction, dense acetowhite to opaque flat epi-
thelium (n = 4), coarse mosaic (n = 1), coarse punctu-
ation (n = 2) or coral-like with internal borders (n = 1).
All CIN3 lesions were associated with HPV16.
Only three CIN2 lesions showed major changes with
coarse punctuation (n = 2) or flat dense acetowhite
(n = 1), and all were associated with HPV16 or HPV18,
while the remaining eight CIN2 lesions showed minor
changes, mainly regular punctuation and flat acetowhite
epithelium. Among cases with normal histology or CIN1
and minor changes (n = 27), no association was demon-
strated between specific HPV types and defined mor-
phological changes on colposcopy.
HPV vaccination
Analysis of HPV vaccination was not useful in the 1983/
84 cohort because of the low number of vaccinated par-
ticipants (42/659). However, 126 of 599 women in the
1988/89 cohort had received a full course of three doses
of HPV vaccines, which was more than expected at the
start of the study. Only two of 126 were diagnosed with
HPV16 infection (1.59%) compared with 42 of 476 non-
vaccinated women (8.82%); the difference was statisti-
cally significant (p = 0.003). There was no CIN associated
with HPV 16 or 18 in the vaccinated group.
Discussion
WOLVES has provided the first real-life data in
Germany on the changing dynamics of HR-HPV and as-
sociated diseases in women aged 20–30 years who have
not been routinely vaccinated. Essentially, the study rep-
resents the final opportunity to monitor a population of
young women at full risk from HPV and provides bench-
mark longitudinal data that will allow the impact of
HPV vaccination to be measured. The overall prevalence
of HR-HPV in this study was 23%. HPV16 was the most
common type in 1983/84 cohort and the second most
common type after HPV51 in the 1988/89 cohort. The
risk for HR-HPV infection was increased by the number
of sexual partners, age at sexual debut and smoking
(weak association). Multivariate analysis demonstrated
that only the number of sexual partners was a significant
risk factor for HPV infection. This finding supports the
concept that the number of sexual partners is the single
most important risk factor for HPV infection, although
other factors may be more important for HPV persist-
ency [19]. Hence, the overall risk of cancer may be more
dependent on cofactors that compromise the interaction
between host and virus [20].
Other national studies in Europe, using heterogeneous
sources and methodologies, have provided HPV prevalence
data in women aged <30 years prior to widespread HPV
vaccination. In a German cross-sectional study [10], 377/
1692 (22.3%) women aged 10–30 years had positive HC2-
HR results (including mixed LR and HR), of whom 239 had
HR-HPV only (14.1%). In the age group 20–22 years rates
were 28.3% for LR/HR and 15.3% for HR only; 95.8% of
women did not show signs of any cervical lesion on cy-
tology. Adjusted analysis identified the number of sexual
partners (OR: 1.105 [95% CI 1.069–1.142]), smoking (OR:
1.508 [1.155-1.968]), and vaccination against HPV (OR:
0.589 [0.398-0.872]) rather than increasing age as risk fac-
tors associated with HPV infection. A UK study used sam-
ples from the National Chlamydia Screening Program
(NCSP) and Prevention of Pelvic Infection (POPI) trial [21].
Of 3829 samples, 3554 (2369 + 1185) were from women
aged 16–24 years. The prevalence of HR-HPV infection
was 34.6% (17.6% HPV16 and 18) in NCSP and 18.2%
(7.2% HPV16 and 18) in POPI. The risk of HR-HPV infec-
tion was increased in women who reported at least two
sexual partners. The CLEOPATRE study included women
aged 18–64 years in Spain and Portugal [22,23]. The
highest prevalence of HR-HPV was observed in women
aged 18–24 years (27.0–28.8%) [23]. The lifetime number
of sexual partners was a strong predictor of HPV infection
(OR 5.44 for 5–10 partners versus one partner; p < 0.001).
In other European studies of non-vaccinated women
aged 18 to <30 years, the prevalence of HR-HPV varied
considerably from <10% to >50% [24-32]. It is important
to note that observed prevalence rates are highly de-
pendent on the methods used for HPV testing. Neverthe-
less, overall, these data show that HR-HPV infection is
relatively common in young women who have not re-
ceived HPV vaccination and that the number of sexual
partners is consistently a strong risk factor for infection.
From a clinical perspective, there is still a significant popu-
lation of young women infected with HR-HPV who will
have a higher rate of cervical screening abnormalities and,
ultimately, an increased risk of developing cancer.
With its well-defined target population, the ongoing
WOLVES study has a number of advantages compared
with one-time, cross-sectional studies in mixed screen-
ing populations. The 1988/89 cohort will be followed by
annual examination for 5 years. In 2014/15, women born
in 1993/94 will be invited for a one-time examination.
WOLVES will finally comprise three different age co-
horts (women born in 1983/84, 1988/89 and 1993/94)
allowing a comparison of changes over time. At the end
of the trial in 2014/15, the 1993/94 cohort will be as old
as the 1988/89 cohort was at the beginning of the trial
in 2009, while the 1988/89 cohort will be as old as the
1983/84 cohort was in 2009.
A particular strength of the WOLVES study design
is careful monitoring of defined patient pathways in par-
ticipants with abnormal screening results or clinical
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findings. As a result, compliance was high and almost
90% of referred participants underwent a colposcopy
examination. A strong association (Mann Whitney
0.3388) was found between HPV16 infection and ASC-
US (>PapII), LISL, and CIN + in 1983/84 cohort, but
only for ASC-US (>PapII) in 1988/89 cohort. This age-
related pattern is probably explained by a high persist-
ency rate and increased risk of oncogenic transformation
over time, consistent with observations reported by
Kjaer and colleagues showing that the increased risk of
CIN3 or cancer associated with HR-HPV infection, espe-
cially HPV16, is a continuous trend over several decades
[33]. Furthermore, data from the HERACLES and
SCALE studies have confirmed the predominant import-
ance of HPV16 infection in both high-grade CIN and in-
vasive cervical cancer [34]. Along with findings from a
recent analysis that demonstrated a higher prevalence of
HPV16 associated with younger age in women with
CIN3 [35], the data from the WOLVES study fit per-
fectly with the proposed theory that HPV16 infection is
the predominant cause of CIN3 in young women. In the
WOLVES study, other HR-HPV types (39, 51, 53 and
66) showed weak associations with abnormal Pap find-
ings and are unlikely to be clinically relevant. It remains
important to assess risk accurately so that clinically
irrelevant abnormal Pap findings do not lead to an
increased risk of over-diagnosis and over-treatment in
young women [16].
An association between HPV52 and LSIL or more was
observed in the 1988/89 cohort, but not in 1983/84
cohort. LSIL can result from harmless transient HPV in-
fections and the difference between cohorts is most
likely to be a chance finding. An imbalance in conization
history between the 1983/84 and 1988/89 cohorts can be
explained by the conservative policy adopted in the col-
poscopy clinic in Wolfsburg, which has been the referral
center for most cases of abnormal smears in the city for
more than 8 years. The corresponding figures in other
German regions may be significantly higher.
Correlative data for HPV infection and associated
pathological abnormalities will help to further refine the
clinical management of young women at risk for malig-
nancies associated with HR-HPV infection, especially
HPV16. The data from the WOLVES study support rec-
ommendations for a later start of cervical screening, at
the age of 25 years or later, no routine HPV testing
in women younger than 25 years and conservative man-
agement of individuals presenting with abnormal Pap
smears. In addition, preliminary data from the WOLVES
study showed that HPV vaccination significantly reduces
the rate of HPV16 infection, corroborating recent data
from a national study in Australia [36].
A limitation of this first analysis of the WOLVES study
is that it provides only prevalence data and as yet does not
show the dynamics of HPV infection and changes in path-
ology findings over time. Nevertheless, the WOLVES data
are in accordance with published data from similar
European trials of HPV types commonly associated with
atypical Pap smears/cervical neoplasia [28,29,37,38] and
support the concept that HR-HPV infections leading to
the development of cancer are acquired early in young
women who have not been vaccinated. A planned analysis
in 2014/15 will provide data on the dynamics of HPV
infection and additional correlative clinical findings in a
population at full risk from HR-HPV-related malignant
disease.
Conclusions
Only a high number of sexual partners (>5) was an inde-
pendent risk factor for HPV infection. The effect of cofac-
tors for the risk of CIN3 and cancer, such as smoking and
use of contraceptives, may not yet be apparent because
these factors probably trigger HPV persistency rather than
acquisition. There was a high prevalence of HR-HPV in-
fection in women aged 20 and 25 years in 2009, which
was associated with an increased risk of abnormal Pap
smears and biopsy proven CIN2+. Women with HPV16
infection have a high risk of clinically relevant lesions that
seems to increase over time (as the comparison of the two
age cohorts shows) and there was a significant impact of
HPV vaccination on HPV16 infections, although the ma-
jority of these women must have been sexually active
already at the time of vaccination and, therefore, the effi-
ciency must be considered to be suboptimal.
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